Medtronic Dirección

Dirección controles de criterios 3/4

El CEO de Medtronic's es Geoff Martha , nombrado en Apr 2020, tiene una permanencia de 4.42 años. compensación anual total es $15.39M, compuesta por 8.8% salario y 91.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.004% de las acciones de la empresa, por valor de $4.47M. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 9.3 años, respectivamente.

Información clave

Geoff Martha

Chief Executive Officer (CEO)

US$15.4m

Compensación total

Porcentaje del salario del CEO	8.8%
Permanencia del CEO	4.1yrs
Participación del CEO	0.004%
Permanencia media de la dirección	3.3yrs
Promedio de permanencia en la Junta Directiva	9.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Geoff Martha en comparación con los beneficios de Medtronic?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jan 26 2024	n/a	n/a	US$4b
Oct 27 2023	n/a	n/a	US$4b
Jul 28 2023	n/a	n/a	US$4b
Apr 28 2023	US$15m	US$1m	US$4b
Jan 27 2023	n/a	n/a	US$4b
Oct 28 2022	n/a	n/a	US$4b
Jul 29 2022	n/a	n/a	US$5b
Apr 29 2022	n/a	n/a	US$5b
Jan 28 2022	n/a	n/a	US$5b
Oct 29 2021	n/a	n/a	US$5b
Jul 30 2021	n/a	n/a	US$4b
Apr 30 2021	US$18m	US$1m	US$4b
Jan 29 2021	n/a	n/a	US$3b
Oct 30 2020	n/a	n/a	US$4b
Jul 31 2020	n/a	n/a	US$4b
Apr 24 2020	US$6m	US$905k	US$5b
Jan 24 2020	n/a	n/a	US$5b
Oct 25 2019	n/a	n/a	US$5b
Jul 26 2019	n/a	n/a	US$4b
Apr 26 2019	US$4m	US$693k	US$5b

Compensación vs. Mercado: La compensación total de Geoff($USD15.39M) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD5.53M).

Compensación vs. Ingresos: La compensación de Geoff ha sido consistente con los resultados de la empresa en el último año.

CEO

Geoff Martha (53 yo)

4.1yrs

Permanencia

US$15,394,632

Compensación

Mr. Geoffrey Straub Martha, also known as Geoff, serves as Director at Medtronic plc since November 01, 2019 and serves as its Chief Executive Officer since April 27, 2020. He serves as Chairman at Medtron...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Geoffrey Martha	Chairman of the Board & CEO	4.1yrs	US$15.39m	0.0042% $ 4.5m
Karen Parkhill	Executive VP & CFO	7.9yrs	US$6.12m	0.0050% $ 5.4m
Sean Salmon	Executive VP & President of Cardiovascular Portfolio	no data	US$5.36m	0.0019% $ 2.0m
Robert J. ten Hoedt	Executive VP & President of Global Regions	9.3yrs	US$5.05m	0.0024% $ 2.6m
Mark Ploof	Senior Vice President of Global Operations and Business Services	7.6yrs	sin datos	sin datos
Jennifer Kirk	Senior VP	2.9yrs	sin datos	0.00099% $ 1.1m
Kenneth Washington	Senior VP and Chief Technology & Innovation Officer	less than a year	sin datos	sin datos
Laura Mauri	Senior VP and Chief Scientific	2.1yrs	sin datos	sin datos
Ryan Weispfenning	VP & Head of Investor Relations	8.9yrs	sin datos	sin datos
Ivan Fong	Executive VP	2.3yrs	US$11.72m	0.00082% $ 889.5k
Torod Neptune	Senior VP & Chief Communications Officer	3.3yrs	sin datos	sin datos
Matt Walter	Chief Human Resources Officer	less than a year	sin datos	sin datos

3.3yrs

Permanencia media

58yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0Y6X se considera experimentado (3.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Geoffrey Martha	Chairman of the Board & CEO	4.5yrs	US$15.39m	0.0042% $ 4.5m
Scott Donnelly	Independent Director	11.3yrs	US$365.01k	0.0010% $ 1.1m
Kendall Powell	Independent Director	17.3yrs	US$350.01k	0.0014% $ 1.5m
Randall Hogan	Independent Director	9.3yrs	US$385.01k	0.0031% $ 3.4m
Craig Arnold	Lead Independent Director	9.3yrs	US$410.01k	0.0026% $ 2.8m
Denise O'Leary	Independent Director	24.3yrs	US$375.01k	0.0058% $ 6.3m
Andrea Goldsmith	Independent Director	5.2yrs	US$370.01k	0.00033% $ 358.0k
Elizabeth Nabel	Independent Director	10.3yrs	US$370.01k	0.00089% $ 965.4k
Lidia Fonseca	Independent Director	1.9yrs	US$294.37k	sin datos
Kevin Lofton	Independent Director	3.7yrs	US$370.01k	0.00018% $ 195.2k
Gregory Lewis	Independent Director	less than a year	sin datos	sin datos

9.3yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de 0Y6X se considera experimentada (9.3 años de antigüedad promedio).

Medtronic Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Medtronic plc Appoints Greg Lewis as New Director

Medtronic plc Appoints Ken Washington as Chief Technology and Innovation Officer

Recent updates

Medtronic plc Receives FDA Approval for Inceptiv Closed-Loop Spinal Cord Stimulator

Medtronic plc Announces New Advancements in Artificial Intelligence for Endoscopic Care by Unveiling ColonPRO

Medtronic plc Announces SMART Trial One-Year Data Demonstrates Medtronic Evolut™ Tavr Platform as Optimal Treatment for Severe Aortic Stenosis in Patients with Small Annulus, Which Is Primarily Women

Upcoming dividend of US$0.69 per share

Third quarter dividend of US$0.69 announced

Medtronic plc Presents New Clinical and Real-World Data on the MiniMed™ 780G System from Around the World

Medtronic plc Approves Cash Dividend for the Fourth Quarter of Fiscal Year 2024, Payable on April 12, 2024

Third quarter 2024 earnings released: EPS: US$0.99 (vs US$0.92 in 3Q 2023)

Medtronic plc to Report Q3, 2025 Results on Feb 18, 2025

Medtronic plc Announces FDA Approval of Its Percept™? RC Deep Brain Stimulation System

Medtronic Diabetes Announces World's First Approval for MiniMed™ 780G System with Simplera Sync™ Disposable, all-in-one sensor

Medtronic plc Announces FDA Approves the PulseSelect Pulsed Field Ablation System for the Treatment of Both Paroxysmal and Persistent Atrial Fibrillation

Upcoming dividend of US$0.69 per share at 3.5% yield

Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2024, Payable on January 12, 2024

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2024

Second quarter 2024 earnings released: EPS: US$0.68 (vs US$0.32 in 2Q 2023)

Now 20% undervalued after recent price drop

Medtronic plc Announces Four-Year Results from the Evolut Low Risk Trial

Now 21% undervalued after recent price drop

Orchestra BioMed Holdings, Inc Grants FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Upcoming dividend of US$0.69 per share at 3.4% yield

Medtronic Issues Statement on the FDA Circulatory Systems Devices Advisory Panel vote for the Symplicity Spyral Renal Denervation System

Medtronic plc Raises Earnings Guidance for 2024

First quarter 2024 earnings released: EPS: US$0.59 (vs US$0.70 in 1Q 2023)

Medtronic plc Approves Cash Dividend for the Second Quarter of Fiscal Year 2024, Payable on October 13, 2023

Full year 2023 earnings released: EPS: US$2.83 (vs US$3.75 in FY 2022)

Medtronic plc Appoints Greg Lewis as New Director

Medtronic plc Presents New Data on MiniMed 780G System on Fixed Meal Dosing and Real-World Time in Range Across Wide Range of Users

Upcoming dividend of US$0.69 per share at 3.1% yield

Upcoming dividend of US$0.69 per share at 3.1% yield

Medtronic plc Appoints Ken Washington as Chief Technology and Innovation Officer

Medtronic plc Approves Cash Dividend for the First Quarter of Fiscal Year 2024, Payable on July 14, 2023

Full year 2023 earnings released: EPS: US$2.83 (vs US$3.75 in FY 2022)

Medtronic plc Announces Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Upcoming dividend of US$0.68 per share at 3.5% yield

Third quarter 2023 earnings released: EPS: US$0.92 (vs US$1.10 in 3Q 2022)

Medtronic plc to Report Q3, 2024 Results on Feb 20, 2024

Medtronic Linq Insertable Cardiac Monitor Detects 10 Times More Atrial Fibrillation in Ischemic Stroke Patients At Three Years Compared to Standard of Care

Siemens Healthineers, GE Healthcare Studying Potential Deals with Medtronic's Spun Off Units

Medtronic Announces First Patient Enrolled in U.S. Clinical Trial for Hugo™ Robotic-Assisted Surgery System

Upcoming dividend of US$0.68 per share

Medtronic plc Approves Cash Dividend for the Third Quarter of Fiscal Year 2023, Payable on January 13, 2023

Medtronic Completes Enrollment in Pivotal Trial Evaluating First-Of-Its-Kind Pulsed Field Ablation Catheter for Patients with Atrial Fibrillation

Second quarter 2023 earnings released: EPS: US$0.32 (vs US$0.97 in 2Q 2022)

Medtronic plc Provides Revenue Results for the Second Half of 2023

Medtronic's SPYRAL HTN-ON MED Study Demonstrates Meaningful Clinical Benefits Consistent with Other SPYRAL HTN Renal Denervation Trials

Medtronic plc Launches of Medtronic Neurovascular Co-Lab Platform to Accelerate Innovation in Stroke Treatment

dorsaVi Partners with Medtronic to Develop New Technology

Medtronic plc Introduces New Program Called My Insights Exclusively Made for Individuals Using MiniMed™ 770G System

Medtronic plc to Receive FDA Approval for Pacing the Heart's Natural Conduction System

Now 21% undervalued after recent price drop

Medtronic plc Receives FDA Clearance for Expanded Indication of LINQ II™ Insertable Cardiac Monitor for Use in Pediatric Patients Ages 2 and Older

Medtronic plc Announces SYMPLICITY HTN-3 Trial Data Show Sustained Long-Term Blood Pressure Reductions with Medtronic Renal Denervation Procedure

Upcoming dividend of US$0.68 per share

Kessler Topaz Meltzer & Check, LLP Files Securities Fraud Class Action Lawsuit Against Medtronic plc

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad